396
Views
71
CrossRef citations to date
0
Altmetric
Review

Anemia in the frail, elderly patient

Pages 319-326 | Published online: 17 Mar 2016

Abstract

Anemia and frailty are two common findings in geriatric patients and have been shown to be associated with poor outcomes in this patient group. Recent studies have contributed to the growing evidence of a possible association with the age-related chronic inflammatory status known as “inflammaging”. These findings do not only give a better insight into the pathogenesis of anemia in frailty, but also offer new treatment options. The present article focuses on this assumed association between anemia, frailty, and inflammaging and summarizes current management options for anemia in frail patients.

Introduction

With the rise of age in Western populations, health care systems and physicians will be increasingly confronted with special age-associated health conditions, comorbidities, and syndromes demanding different diagnostic and therapeutic approaches compared to younger patients. Anemia and frailty are two common syndromes in older patients,Citation1 both describing a state of unphysiologic deficiency and imbalance: “anemia” derives from the Greek terms “αν-“, meaning “no”, and “-αιμία”, meaning “blood”, describing a lack of red blood cells; “frailty” derives from the Latin term “fragilitas”, meaning “ephemerality” and “weakness”, indicating a state of vulnerability predisposing to adverse outcomes.Citation1 Besides their association with advanced age, their increased prevalence among older people, and their association with functional decline and adverse outcomes, several recent studies have also revealed an association between anemia, frailty, and the age-associated state of chronic inflammation, based on immunosenescence.Citation2Citation5 This process of “inflammaging” is characterized by an age-associated chronic upregulation of the inflammatory immune response with increased levels of proinflammatory cytokines like interleukin-1 (IL-1), IL-6, and tumor necrosis factor (TNF).Citation2,Citation4 Inflammaging is believed to be a consequence of a lifetime exposure to antigenic load and environmental free radicals, resulting in a chronic proinflammatory state.Citation4 The present article focuses on this association between anemia, frailty, and inflammaging.

Anemia in the aged

The term “anemia” describes a lack of red blood cells, associated with reduced levels of hematocrit and hemoglobin (Hb). Hb is an iron-containing metalloprotein responsible for the physiologic transportation of oxygen inside the red blood cells throughout the human body.Citation6 A lack of oxygen is known to be fatal for human organs and may cause malfunction and, if it persists, even organ failure.Citation7 Anemia is therefore an unphysiologic state that has to be compensated. While anemic younger patients may rely upon their organ reserves to compensate the lack of oxygen, anemic older patients >65 years appear rather disadvantaged on this point, because aging is associated with a progressive loss of functional organ reserves, increasing the risk of frailty.Citation8

Anemia is a frequent finding in older patients and has been shown to be associated with increased physical impairment,Citation9,Citation10 frailty,Citation11 cognitive decline,Citation12 depression,Citation13 and mortality.Citation14 Several international studies have shown that the prevalence of anemia varies depending on the population considered: A study of the third National Health and Nutrition Examination Survey (NHANES III 1991–1994) showed an anemia prevalence of >20% among community-dwelling seniors >85 years.Citation15 A more recent study among Indian home-dwelling people was consistent with this finding,Citation16 while a systematic review by Gaskell et alCitation17 among geriatric inpatients >65 years living in developed countries found an anemia prevalence of up to 40%. A large Austrian epidemiologic study showed a comparable prevalence of anemia among Austrian geriatric inpatients aged ≥90 years.Citation18 Our own research group found even higher prevalence rates of >50% in German geriatric inpatients aged ≥70 years,Citation19,Citation20 which is consistent with Spanish findings among geriatric inpatients.Citation21 Preliminary results of the first German multi-center study on anemia prevalence among geriatric inpatients found a prevalence of >55% and confirmed the previous findings of the monocentric studies.Citation22

According to NHANES III, anemia can be roughly divided into three subtypes: anemias with nutrient deficiency like iron, folate, or vitamin B12 deficiency; anemias without nutrient deficiency like renal anemia (RA) or anemia of chronic inflammation (ACI); and anemias that cannot be classified and are therefore called “unexplained anemias” (UAs).Citation15 Each of the subtypes formed one-third of all anemias in NHANES III. Results of the large Austrian epidemiologic study on older patients revealed ACI to be the most prevalent subtype with 62.1%.Citation18 This finding was confirmed by the German multicenter study on anemia prevalence among geriatric inpatients.Citation22

Anemia with nutrient deficiency is often associated with malnutrition, which is an important health-affecting factor among older patients. A review by Ahmed and HaboubiCitation23 gives a broad insight into the age-associated biophysiological changes of the digestive system. Age-associated changes in the gastrointestinal tract as well as polymedication, depression, or social isolation are risk factors for malnutrition in older patients,Citation23 resulting in anemia-relevant deficiency of micronutrients like iron, folic acid, vitamin B12, zinc, and copper.Citation24

UA is considered an exclusion diagnosis due to lack of clear consensus on its clinical or experimental approach. Makipour et al reviewed a number of potential causes, including androgen insufficiency, stem cell aging, and myelodysplasia.Citation25

ACI underlies the focus of the present review and will be the subject of the next section.

In most of the epidemiologic studies on anemia in the aged, WHO criteria are applied to define anemia with women being anemic if Hb <12 g/dL and men being anemic if Hb <13 g/dL. However, the validity of these reference values for older patients, which were developed >40 years ago by a WHO expert group,Citation26 is controversial.Citation27Citation29 Several studies have shown that application of WHO criteria for anemia definition is not appropriate for aged patients.Citation27,Citation29 Not only was a reverse J-shaped association between Hb and risk for all-cause mortality shown,Citation27,Citation28 but also an increasing mortality risk at elevated Hb levels.Citation28 There is an ongoing quest for what can be considered a normal Hb reference value in older patients.

Current insights into ACI

ACI, also known as anemia of chronic diseases, is the most common type of anemia in older patients. It is usually found in diseases associated with immune activation such as infections, autoimmune disorders, or age-associated inflammaging.Citation30 The development of ACI is assumed to result from the interaction of several factors: iron retention in cells of the reticuloendothelial system (RES) makes the metal unavailable for erythropoiesis. This retention is mediated by inflammation-associated excessive elevation of the iron-regulatory peptide hepcidin, inhibiting the release of iron from RES cells.Citation31 Hepcidin is responsible for the downregulation of the iron export protein ferroportin. Thus, iron remains “locked up” in the stores, resulting in a state of functional iron deficiency. Despite hepcidin-dependent iron limitation being considered to be the key factor in the development of ACI, the exact mechanisms underlying the blockade of erythropoiesis during inflammation are not well understood yet. Recent studies have focused on the bone marrow microenvironment, having a vital influence on the development of hematopoietic stem cells (HSCs).Citation32 There is increasing knowledge that the cells of the bone marrow microenvironment produce factors and cytokines which are important for the self-renewal and survival of HSCs and that they can sense the hematopoietic needs of the organism, adapting the hematopoietic processes to the needs. Cells of the bone marrow microenvironment act as regulators of the hematopoietic differentiation, based on a complex interaction of cytokines.Citation32 The release of inflammatory cytokines like IL-6, IL-1, TNFα, and interferon γ (IFNγ) triggers ACICitation33,Citation34 by an increase of myelopoiesis at the expense of erythropoiesis, which is reduced and finally arrested.Citation32 It is therefore assumed that systemic chronic inflammations may cause alterations in the bone marrow microenvironment, resulting in altered erythropoiesis.Citation32

Current aspects of frailty

Results from recent studies increasingly suggest an association between immunosenescence, inflammation, and the development of frailty: The age-associated overall change of the immune system is called immunosenescence. According to Franceschi et al,Citation35 inflammaging is part of the immunosenescence process, consisting of an age-associated upregulation of the inflammatory response, resulting in a low-grade proinflammatory state.Citation4 This proinflammatory state is characterized by increased levels of inflammatory cytokines, such as IL-6, IL-1, TNFα, and IFNγ. These cytokines have been shown to rise with ageCitation36 and to be associated with the development of ACICitation32 and other age-associated diseases.Citation37 The process of immunosenescence has been shown to result in increased vulnerability to infectious diseases as well as to susceptibility of inflammation-associated pathologies in connection with, eg, chronic kidney disease, cardiovascular disease, Alzheimer’s disease, or diabetes mellitus.Citation2,Citation4,Citation38 A study by Chang et alCitation2 on the association between inflammatory disease burden and frailty revealed that a higher inflammatory disease count favors the occurrence of frailty in older patients. The consequence of the constant proinflammatory state does not only increase susceptibility to age-related diseases but also makes older patients prone to faster progression of all age-associated diseases.

Before realization of these biochemical insights into the pathogenesis of frailty, the syndrome of frailty experienced a more clinical approach. In the context of geriatrics, frailty describes a decline in physical strength, lean body mass, and power, associated with decreased balance, decreased walking performance, and low activity.Citation39 Frailty has been associated with age for a very long time: The Shakespearean “shrunk shank” implies the age-associated loss of muscle mass or “sarcopenia”. Frailty is considered to be a high risk state for adverse health outcomes. In 2001, Fried et al developed the first definition of frailty, based on the relationship between biologic and age-associated markers, linking in a cycle of frailty, spiraling down through sarcopenia, osteoporosis, and chronic undernutrition to reduced walking speed, weight loss, and finally immobility.Citation39 Based on this finding, frailty is defined by the presence of three of the five “Fried criteria”: exhaustion, weight loss, low activity, slow walking speed, and reduced grip strength.Citation39 A state of pre-frailty is defined by the presence of one or two of the five criteria.Citation39

Recent studies have revealed that additional factors increase the odds for being frail: Results of the San Antonio Longitudinal Study of Aging (SALSA) study showed that the ethnic composition and the economic environment of the neighborhoods of older Mexican Americans influence their chance to be frail.Citation40 Similar findings were made by a French study group, underlining the adverse long-term effects of socioeconomic inequality over the lifetime of healthy aging older French individuals.Citation41 A Spanish study group showed an association between frailty and impaired basic activities of daily living as well as mortality among institutionalized older adults.Citation42 Frailty has been further shown to be associated with polymedicationCitation43 and poor postoperative outcome.Citation44,Citation45 The association with anemia will be discussed in the following paragraph.

Association between anemia, frailty, and inflammaging

Several studies have shown that anemia is associated with functional loss and poor outcome in older patients and has therefore been identified as an additional factor in the development of frailty.Citation1,Citation45,Citation46 While the Fried criteria of frailty were based strictly on biological characteristics,Citation39 the recently developed frailty index (FI) by Ng et alCitation11 also includes socioeconomic and nutritional factors and comorbidities like anemia.Citation11 Among the final 13 frailty predictors of the index were “low Hb” and “elevated white blood cell count (WBC)”, implying the association between frailty, anemia, and inflammation. Indeed, in older patients, anemia and frailty have been shown to share a pathophysiology associated with chronic inflammatory processes,Citation2,Citation47 induced by immunosenescence-associated changesCitation4 and oxidative stress.Citation47 Oxidative stress describes an imbalance between the physiologic oxidant and the antioxidant system of the human body, with prevalence of oxidants. Oxidants are physiologic products of the O2 energy metabolism, which can accumulate in certain disease conditions.Citation47 The so-called “oxygen-free radicals” or reactive oxygen species (ROS) are extremely reactive molecules, causing harm by affecting cell membranes, proteins, enzymes, and DNA where they may alter genetic information.Citation48 A recently published review by BarnesCitation49 focused on the association between inflammaging, age-associated burden of diseases, and oxidative stress. Using the example of COPD, the author underlines the necessity of a multidimensional diagnostic and therapeutic approach based on the knowledge of the underlying molecular age-associated pathways.

Despite this growing awareness of a pathogenetic association between inflammaging, frailty, and anemia in older patients and the finding that anemia predisposes to a poorer disease outcome,Citation50 until now a cause-and-effect relationship between anemia, frailty, and inflammation cannot be established.

A recent review by Wu et al gives an interesting insight into the intertwined association between frailty and inflammaging. The authors underline that aging is a process of deterioration and decline of physical strength, resulting from an individually different lifelong accumulation of intracellular and cellular damage, which may lead to systemic and organic failure.Citation51 At the advanced stage, aging is associated with organ dysfunction, which might easily turn into organ failure in the presence of stress factors. Due to the individual heterogeneity of the aging process, physicians and health carers are in need of biomarkers, indicating the level of organ dysfunction. These biomarkers will allow an optimized prediction of morbidity, mortality, and adverse health outcome in every individual patient. Frailty has been shown to be such a biomarker, indicating that the aging process has reached the level of organ dysfunction if at least three of the five Fried criteria are met.Citation39,Citation51 Inflammaging, as a result of the age-associated immunosenescence, contributes to organ failure at the cellular level due to the associated increase of cytokines. These cytokines might also serve as biomarkers for the advanced aging process. Wu et al give a solid review of studies supporting the biomarking roles of cytokines as well as frailty in the individual health risk management of older patients.Citation51

As mentioned earlier, the pathogenetic association between ACI and inflammaging is based on increased levels of cytokines, possibly released by HSCs. However, until now, anemia has not been generally acknowledged as a biomarker for advanced age. A Spanish study groupCitation52 showed a significant association between the anemia-associated parameter red cell distribution width (RDW) and mortality, with RDW rising during the last 5 years of life. Elevated RDW levels, reflecting an increase of anisocytosis, have been shown to be associated with chronic diseasesCitation53 and chronic inflammation.Citation54 The close relationship of anemia and anemia-associated parameters like RDW with inflammaging and frailty in older patients merits further research regarding their potential role as biomarkers.

Is eryptosis a link?

Erythrocyte suicidal death or eryptosis is a physiologic mechanism to remove defective erythrocytes from blood circulation. It is characterized by cell shrinkage and translocation of phosphatidylserine to the membrane surface, enabling phagocytes to engulf erythrocytes and eliminate them from circulation to prevent hemolysis.Citation55 In their very detailed review article, Lang and Lang described triggers of eryptosis, including oxidative stress and multimorbidity.Citation55 Eryptosis was described in connection with several morbidities like diabetes mellitus, chronic heart disease, chronic renal insufficiency, and dehydration.Citation55 A recent study by Pretorius et alCitation56 focused on the association between eryptosis and the inflammatory signaling in Parkinson’s disease (PD) based on the inflammatory cytokines involved in PD pathophysiology and eryptosis. They showed that erythrocytes of PD patients had a deranged morphology which might be due to eryptosis;Citation56 however, causality could not be explained. An interesting recent study by Lupescu et alCitation57 revealed a significant higher rate of phosphatidylserine presenting erythrocytes in older patients aged 88.6±0.9 years than in younger patients aged 31.3±1.7 years.Citation57 The increase of phosphatidylserine exposition was paralleled by an increase of ROS, representing oxidative stress.Citation57 The authors concluded that anemia of the aged might be due to enhanced eryptosis. Bearing in mind the increased evidence of an association between aging and ROS and the finding of elevated levels of ROS in the heartCitation58 and vasculatureCitation59 of aged patients and the assumed association of ROS with inflammaging,Citation35 the conclusion by Lupescu et alCitation57 sounds highly interesting. Besides the ROS triggers, Lang and LangCitation55 also listed several morbidities like diabetes mellitus, chronic heart disease, chronic renal insufficiency, and dehydration to be associated with eryptosis.Citation55 These comorbidities are often seen in geriatric patients. In the study by Lupescu et al, seven patients suffered from diabetes mellitus, 14 from chronic kidney disease, and four from heart failure.Citation57 These comorbidities might therefore also be held responsible for increased eryptosis. Although until now the exact underlying mechanisms are still unclear, one might assume a close connection between inflammaging, anemia, and frailty () with ROS in the center position, fed by comorbidities and inflammaging; ROS might cause eryptosis, the link to ACI, which has been shown to be the most frequent type of anemia in the aged. The final common path will lead to frailty (). However, this hypothetical context remains to be proven.

Figure 1 Hypothetical association between frailty, ACI, and inflammaging.

Figure 1 Hypothetical association between frailty, ACI, and inflammaging.

Management options for anemia in frail patients

Despite the diverse causes for anemia in the aged, the lowest common denominator of iron deficiency anemia (IDA), ACI, or UA is iron deficiency, either absolute with empty iron stores like in IDA, or functional with the incapacity to release iron from the full iron stores like in ACI. Therefore, iron substitution is still the mostly recommended symptomatic treatment in IDA and ACICitation60 as well as in iron-deficient UA.Citation61 Diagnosis and treatment of the underlying diseases are necessary in IDA and ACI, but interventions should always be adjusted to the individual geriatric patient’s wish and prognosis in a harm–benefit balancing manner, based on comprehensive geriatric assessment results.

Oral iron substitution has been the gold standard in anemia treatment for decades.Citation62 However, the discovery of hepcidin as a key factor in iron homeostasisCitation63,Citation64 and analysis of its role in connection with chronic inflammationCitation64,Citation65 revealed that hepcidin causes functional iron deficiency by binding to and degrading the iron export protein ferroportin.Citation64 This leads to reduced enteral iron resorption and trapping of iron in macrophages and hepatocytes.Citation65 In patients with ACI and inflammation-associated increase of hepcidin, oral iron substitution will therefore be ineffective and intravenous iron substitution is recommended.Citation60 Several recent studies have shown that intravenous iron application is also safe in geriatric patients with chronic inflammation-associated anemia.Citation66Citation68 Oral iron substitution is usually recommended in case of absolute iron deficiency.Citation69 Results of a recent meta-analysis of oral iron substitution in older patients indirectly confirms this recommendation by revealing an increase of Hb after 4–6 weeks of oral iron substitution.Citation70 However, a recent study by Silay et alCitation71 raises doubts if this recommendation of oral iron substitution can be transferred to geriatric patients. In their cross-sectional study of 100 IDA patients divided into the age groups ≥65 years and <65 years, they revealed a significantly lower iron absorption among older patients ≥65 years compared to the younger patient group. A possible association with “inflammaging”Citation35,Citation72 is speculative because underlying reasons remain subject to further research.

According to the transfusion guidelines of the German Medical Association, transfusion of red blood cells is usually indicated in case of severe, symptomatic anemia to prevent hypoxemia.Citation73 A restrictive strategy is recommended in patients without cardiovascular diseases with erythrocyte transfusion only if Hb is <6 g/dL.Citation73 A recent Danish study on erythrocyte transfusion in postoperative orthogeriatric hip fracture patients compared a restrictive (Hb <9.7 g/dL) with a liberal (Hb <11.3 g/dL) transfusion strategy.Citation74 It revealed similar recovery of activities of daily living among the two study groups, but a significantly lower mortality rate in nursing home patients undergoing the liberal erythrocyte transfusion strategy.Citation74 The fact that the Hb threshold of the restrictive strategy group was even above the threshold recommended by the German Medical Association underlines the urgent need for further research on transfusion strategies in geriatric patients to find the appropriate Hb thresholds.

Recent findings about the assumed interaction between immunosenescence and inflammaging, anemia of the aged, the importance of ROS, and the key enzyme of iron metabolism hepcidin have opened new research fields of therapeutic strategies. A very detailed review by Macciò and MadedduCitation47 focuses on the management of ACI in older patients. It highlights the current knowledge about hepcidin-antagonizing agents in ACI to prevent iron trapping and the antagonization of the IL-6 pathway to lower hepcidin levels.Citation47 They concede a potential beneficial effect to endogenous and exogenous antioxidants for the protection against oxidative damage caused by ROS, but also underline the lack of data to issue general recommendation.Citation47

In conclusion, there is growing evidence of a close pathogenetic association between frailty, anemia of the aged, and inflammation, even though the underlying mechanisms still remain unclear. Further research on this field would contribute to new diagnostic and therapeutic strategies and might improve older patients’ outcome.

Disclosure

The author reports no conflicts of interest in this work.

References

  • ArtzASAnemia and the frail elderlySemin Hematol200845426126618809097
  • ChangSSWeissCOXueQLFriedLPAssociation between inflammatory-related disease burden and frailty: results from the Women’s Health and Aging Studies (WHAS) I and IIArch Gerontol Geriatr201254191521763008
  • LengSChavesPKoenigKWalstonJSerum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot studyJ Am Geriatr Soc20025071268127112133023
  • BaylisDBartlettDBPatelHPRobertsHCUnderstanding how we age: insights into inflammagingLongev Healthspan201321824472098
  • BloomerSAKregelKCBrownKEHeat stress stimulates hepcidin mRNA expression and C/EBPα protein expression in aged rodent liverArch Gerontol Geriatr201458114515223993269
  • ShanderAGoodnoughLTJavidrooziMIron deficiency anemia – bridging the knowledge and practice gapTransfus Med Rev201428315616624931617
  • InceCMikEGMicrocirculatory and mitochondrial hypoxia in sepsis, shock and resuscitationJ Appl Physiol (1985)2016120222623526066826
  • AlexaIDIlieACMoroşanuAVoicaAApproaching frailty as the new geriatric syndromeRev Med Chir Soc Med Nat Iasi2013117368068524502035
  • Juárez-CedilloTBasurto-AcevedoLVega-GarcíaSPrevalence of anemia and its impact on the state of frailty in elderly people living in the community: SADEM studyAnn Hematol201493122057206225005679
  • ContrerasMFormigaFFerrerAChiviteDPadrósGMonteroAGrupo OctabaixProfile and prognosis of patients over 85 years old with anemia living in the community. Octabaix StudyRev Esp Geriatr Gerontol201550521121525583243
  • NgTPFengLNyuntMSLarbiAYapKBFrailty in older persons: multisystem risk factors and the Frailty Risk Index (FRI)J Am Med Dir Assoc201415963564224746590
  • HongCHFalveyCHarrisTBAnemia and risk of dementia in older adults: findings from the Health ABC studyNeurology201381652853323902706
  • SonSJLeeKSNaDLAnemia associated with depressive symptoms in mild cognitive impairment with severe white matter hyperintensitiesJ Geriatr Psychiatry Neurol201124316116721856970
  • ZakaiNAFrenchBArnoldAMHemoglobin decline, function, and mortality in the elderly: the cardiovascular health studyAm J Hematol20138815923044913
  • GuralnikJMEisenstaedtRSFerrucciLKleinHGWoodmanRCPrevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemiaBlood200410482263226815238427
  • PaulSSAbrahamVJHow healthy is our geriatric population? A community-based cross-sectional studyJ Family Med Prim Care20154222122525949971
  • GaskellHDerrySAndrew MooreRMcQuayHJPrevalence of anaemia in older persons: systematic reviewBMC Geriatr2008148118194534
  • BachVSchruckmayerGSamIKemmlerGStauderRPrevalence and possible causes of anemia in the elderly: a cross-sectional analysis of a large European university hospital cohortClin Interv Aging20142291187119625092968
  • ZilinskiJZillmannRBeckerIBenzingTSchulzRJRöhrigGPrevalence of anemia among elderly inpatients and its association with multidimensional loss of functionAnn Hematol201493101645165424870940
  • RöhrigGKlossokWBeckerIBenzingTSchulzRJPrevalence of anemia among elderly patients in an emergency room settingEur Geriatr Med20145137
  • Romero-RupertoSPérez-BocanegraMCDuran-TabernaMToscano-RiveraABarbé-Gil OrtegaJSan José-LaporteAAnemia in elderly patients admitted to an acute geriatric wardRev Esp Geriatr Gerontol201550312212525749584
  • RöhrigGRückerYBeckerIAssociation of anemia with functional and nutritional status in the German multicenter study “GeriAnaemie2013”Z Gerontol Geriatr201548S1S14S02 German
  • AhmedTHaboubiNAssessment and management of nutrition in older people and its importance to healthClin Interv Aging2010520721620711440
  • ChanLNMikeLAThe science and practice of micronutrient supplementations in nutritional anemia: an evidence-based reviewJPEN J Parenter Enteral Nutr201438665667224847050
  • MakipourSKanapuruBErshlerWBUnexplained anemia in the elderlySemin Hematol200845425025418809095
  • World Health OrganizationNutritional anaemias. Report of a WHO scientific groupWorld Health Organ Tech Rep Ser19684055374975372
  • ZakaiNAKatzRHirschCA prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health StudyArch Intern Med2005165192214222016246985
  • CulletonBFMannsBJZhangJTonelliMKlarenbachSHemmelgarnBRImpact of anemia on hospitalization and mortality in older adultsBlood2006107103841384616403909
  • BeutlerEWaalenJThe definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration?Blood200610751747175016189263
  • HuntKJWalshBMVoegeliDRobertsHCInflammation in aging part 2: implications for the health of older people and recommendations for nursing practiceBiol Res Nurs201011325326019934108
  • TheurlISchrollASonnweberTPharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in ratsBlood2011118184977498421730356
  • GomesACGomesMSHematopoietic niches, erythropoiesis and anemia of chronic infectionExp Hematol Epub20151122
  • LibregtsSFGutiérrezLde BruinAMChronic IFN-γ production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axisBlood201111892578258821725055
  • FelliNPediniFZeunerAMultiple members of the TNF super-family contribute to IFN-gamma-mediated inhibition of erythropoiesisJ Immunol200517531464147216034083
  • FranceschiCBonafèMValensinSInflamm-aging. An evolutionary perspective on immunosenescenceAnn N Y Acad Sci200090824425410911963
  • VastoSCandoreGBalistreriCRInflammatory networks in ageing, age-related diseases and longevityMech Ageing Dev20071281839117118425
  • De MartinisMFranceschiCMontiDGinaldiLInflammation markers predicting frailty and mortality in the elderlyExp Mol Pathol200680321922716460728
  • WeiskopfDWeinbergerBGrubeck-LoebensteinBThe aging of the immune systemTranspl Int200922111041105019624493
  • FriedLPTangenCMWalstonJCardiovascular Health Study Collaborative Research GroupFrailty in older adults: evidence for a phenotypeJ Gerontol A Biol Sci Med Sci2001563M146M15611253156
  • EspinozaSEHazudaHPFrailty prevalence and neighborhood residence in older Mexican Americans: the San Antonio longitudinal study of agingJ Am Geriatr Soc201563110611125597562
  • HerrMRobineJMAegerterPArvieuJJAnkriJContribution of socioeconomic position over life to frailty differences in old age: comparison of life-course models in a French sample of 2,350 old peopleAnn Epidemiol2015259674680.e126117589
  • de la Rica-EscuínMGonzález-VacaJVarela-PérezRFrailty and mortality or incident disability in institutionalized older adults: the FINAL studyMaturitas201478432933424929996
  • RungangaMPeelNMHubbardREMultiple medication use in older patients in post-acute transitional care: a prospective cohort studyClin Interv Aging2014291453146225214773
  • AmblerGKBrooksDEAl ZuhirNEffect of frailty on short-and mid-term outcomes in vascular surgical patientsBr J Surg2015102663864525764503
  • KimSWHanHSJungHWMultidimensional frailty score for the prediction of postoperative mortality riskJAMA Surg2014149763364024804971
  • SilvaJCMoraesZVSilvaCUnderstanding red blood cell parameters in the context of the frailty phenotype: interpretations of the FIBRA (Frailty in Brazilian Seniors) studyArch Gerontol Geriatr201459363664125236441
  • MacciòAMadedduCManagement of anemia of inflammation in the elderlyAnemia2012201256325123091709
  • AzziADaviesKJAKellyFFree radical biology – terminology and critical thinkingFEBS Lett20045581–33614982062
  • BarnesPJMechanisms of development of multimorbidity in the elderlyEur Respir J201545379080625614163
  • OkaforUHUnuigbeEICardio-renal-anemia syndrome: a report of three casesSaudi J Kidney Dis Transpl201223356256822569446
  • WuICLinCCHsiungCAEmerging roles of frailty and inflammaging in risk assessment of age-related chronic diseases in older adults: the intersection between aging biology and personalized medicineBiomedicine (Taipei)201551125722960
  • Martínez-VelillaNCambra-ContinKGarcía-BaztánAAlonso-RenedoJHercePAIbáñez-BeroizBChange in red blood cell distribution width during the last years of life in geriatric patientsJ Nutr Health Aging201519559059425923491
  • PatelKVSembaRDFerrucciLRed cell distribution width and mortality in older adults: a meta-analysisJ Gerontol A Biol Sci Med Sci201065325826519880817
  • HuDRenJWangGGuGLiGLiuSValue of red cell distribution width for assessing disease activity in Crohn’s diseaseAm J Med Sci20153491424525171547
  • LangELangFTriggers, inhibitors, mechanisms, and significance of eryptosis: the suicidal erythrocyte deathBiomed Res Int20152015513518
  • PretoriusESwanepoelACBuysAVVermeulenNDuimWKellDBEryptosis as a marker of Parkinson’s diseaseAging (Albany NY)201461078881925411230
  • LupescuABissingerRGoebelTEnhanced suicidal erythrocyte death contributing to anemia in the elderlyCell Physiol Biochem201536277378326021265
  • JudgeSYoungMJSmithAHagenTLeeuwenburghCAge-associated increases in oxidative stress and antioxidant enzyme activities in cardiac interfibrillar mitochondria: implications for the mitochondrial theory of agingFASEB J200519341942115642720
  • UngvariZOroszZLabinskyyNIncreased mitochondrial H2O2 production promotes endothelial NF-κB activation in aged rat arteriesAm J Physiol Heart Circ Physiol20072931H37H4717416599
  • MetzgerothGHastkaJIron deficiency anemia and anemia of chronic disordersInternist (Berl)201556997898826228317
  • DahlerupJFEivindsonMJacobsenBADiagnosis and treatment of unexplained anemia with iron deficiency without overt bleedingDan Med J2015624C507225872536
  • PoetesJOral iron therapy in hemorrhagic, infectious and tumorous anemiasHippokrates1954252065165213232584
  • KulaksizHTheiligFBachmannSThe iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidneyJ Endocrinol2005184236137015684344
  • NemethEValoreEVTerritoMSchillerGLichtensteinAGanzTHepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase proteinBlood200310172461246312433676
  • GangatNWolanskyjAPAnemia of chronic diseaseSemin Hematol201350323223823953340
  • BachMGeiselTMartinJEfficacy and safety of intravenous ferric carboxymaltose in geriatric inpatients at a German tertiary university teaching hospital: a retrospective observational cohort study of clinical practiceAnemia2015201564793026236500
  • RöhrigGSteinmetzTSteinJEfficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studiesMMW Fortschr Med2014156Suppl 2485325351027
  • ReedJCharytanCYeeJThe safety of intravenous iron sucrose use in the elderly patientConsult Pharm200722323023817658969
  • HastkaJHeimpelHMetzgerothGEisenmangel und Eisenmangelanämie [Onkopedia guideline] Available from: https://www.onkopedia.com/de/onkopedia/guidelines/eisenmangel-und-eisenmangelanaemieAccessed October 23, 2015 German
  • TayHSSoizaRLSystematic review and meta-analysis: what is the evidence for oral iron supplementation in treating anaemia in elderly people?Drugs Aging201532214915825644019
  • SilayKAkinciSYalcinAThe status of iron absorption in older patients with iron deficiency anemiaEur Rev Med Pharmacol Sci201519173142314526400514
  • FranceschiCCampisiJChronic inflammation (inflammaging) and its potential contribution to age-associated diseasesJ Gerontol A Biol Sci Med Sci201469Suppl 1S4S924833586
  • German Medical Association(Bundesärztekammer): Guidelines of the German Medical Association for Therapy with Blood Components and Plasma Derivatives4th revised editionGerman Medical Publishers (Deutscher Ärzte Verlag)2014 Chapters 11019 German
  • GregersenMBorrisLCDamsgaardEMBlood transfusion and overall quality of life after hip fracture in frail elderly patients – the transfusion requirements in frail elderly randomized controlled trialJ Am Med Dir Assoc201516976276625933728